Dr Reddy's gets EIR from USFDA for Cuernavaca plant in Mexico
New Delhi: Drug firm Dr Reddy's Laboratories said it has received establishment inspection report from the US health regulator for its Cuernavaca facility in Mexico.
The company had earlier said in a regulatory filing that audit of its active pharmaceutical ingredient (API) Cuernavaca plant in Mexico by the United States Food and Drug Administration (USFDA) was completed with zero observations.
"...we have received an Establishment Inspection Report (EIR) from the USFDA, for the above-referred facility," Dr Reddy's Laboratories said in a filing to the BSE.
As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd